Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{182852,
        author = {Dr. P S Chandra Shekar and Dr. G. Raghavendra and Dr. R. SIDDESWARI},
        title = {Comparative Outcomes of Ventilator-Associated Pneumonia in Diabetic and Non-Diabetic Patients: A Prospective Observational Study},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {2},
        pages = {3587-3589},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=182852},
        abstract = {Background: Ventilator-associated pneumonia (VAP) is a leading nosocomial infection in intensive care units (ICUs), with significant morbidity and mortality. Diabetes mellitus (DM) is a potential risk factor, but its impact on VAP outcomes remains underexplored.
Objective: To compare outcomes (survival, recovery time, and microbial profiles) of VAP in diabetic and non-diabetic patients.
Methods: A prospective observational study was conducted from June 2022 to June 2024 at ASRAM Medical College, Eluru, involving 50 mechanically ventilated patients (25 with Type 2 DM, 25 non-diabetic) who developed VAP. Data on demographics, microbial cultures (blood and tracheal), survival, and recovery duration were analyzed using SPSS version 26, with a p-value < 0.05 considered significant.
Results: Diabetic patients had a significantly lower survival rate (24% vs. 80%, p = 0.000166) and longer recovery time (7 days vs. 5 days, p < 0.05) compared to non-diabetic patients. Pathogens such as Streptococcus pneumoniae, Pseudomonas aeruginosa, and various Staphylococcus species showed 100% mortality in diabetic patients, while non-diabetic patients had lower mortality rates (e.g., P. aeruginosa: 28%). Poor glycemic control (HbA1c > 10%) was associated with higher mortality (91.7% vs. 61.5%, p < 0.05).
Conclusion: Type 2 DM is a significant risk factor for adverse VAP outcomes, with increased mortality and prolonged recovery. Tailored antimicrobial strategies and glycemic control are critical for improving prognosis in diabetic VAP patients.},
        keywords = {Ventilator-associated pneumonia, Diabetes mellitus, Mortality, Microbial profile, Intensive care unit},
        month = {July},
        }